Vogelzang agreed: "The synergistic benefit will have to be demonstrated, but it is very plausible that combining and sequencing these agents may add even more value than what we see here." He was a co-investigator on the Ra-223 study.
Findings presented at medical meetings are typically considered preliminary until they have been published in a peer-reviewed journal.
More information
There's much more on prostate cancer at the American Cancer Society.
Copyright © 2012 HealthDay. All rights reserved.
Reader Comments